Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | MMP1 | P03956 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067761 | 1.00 | SLC7A11 (1.00) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL8069397 | 0.88 | SLC7A11 (0.79) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL8069398 | 0.88 | SLC7A11 (0.79) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL8069199 | 0.88 | SLC7A11 (0.78) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL8069200 | 0.88 | SLC7A11 (0.78) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL8071847 | 0.86 | SLC7A11 (0.75) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL8071849 | 0.86 | SLC7A11 (0.75) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL30758844 | 0.85 | SLC7A11 (0.74) | SLC7A11LMNAMEN1KMT2AABCC3 | |
| SCHEMBL29759524 | 0.83 | SLC7A11 (0.71) | SLC7A11MEN1KMT2AALDH1A1TSHR | |
| Sulfapyridine SCHEMBL10336229 | 0.83 | SLC7A11 (0.71) | SLC7A11LMNAMEN1KMT2AABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-06 | — | — | US | disclosed |
| EP-0613468-B1 | Substituted salicylic acids for the treatment of autoimmune diseases | PHARMACIA & UPJOHN AB (SE) | 2000-07-12 | — | — | EP | disclosed |
| US-5556855-A | TREATMENT OF AUTOIMMUNE DISEASES | PHARMACIA AB (SE) | 1996-09-17 | — | — | US | disclosed |
| US-5403930-A | Chemical intermediate for drugs used in autoimmune diseases | PHARMACIA AB (SE) | 1995-04-04 | — | — | US | disclosed |
| EP-0613468-A1 | NOVEL SUBSTITUTED SALICYCLIC ACIDS | Pharmacia & Upjohn Aktiebolag (SE) | 1994-09-07 | — | — | EP | disclosed |
| US-5302718-A | Used for treating autoimmune diseases | KABI PHARMACIA AB (SE) | 1994-04-12 | — | — | US | disclosed |
| WO-1993010094-A1 | NOVEL SUBSTITUTED SALICYCLIC ACIDS | KABI PHARMACIA AB (SE) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | NFKBIA, NFKB2, IKBKG | SLC7A11 4544/4885LMNA 3200/4885MEN1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.